Xuan Che

No ORCID on file · 16 papers in corpus · active 2012-2025

Study types

  • article 12
  • other 3
  • preprint 1

Condition tags

  • endometriosis 9
  • adenomyosis 9
  • dysmenorrhea 3
article 2025
Science China. Life sciences ·doi:10.1007/s11427-025-2981-1

Adenomyosis remains a challenging gynecological disorder to investigate due to the absence of in vitro models that accurately replicate endometrial tissue dynamics across the menstrual cycle. To address this gap, we established an endometri…

other 2025
Scientific reports ·doi:10.1038/s41598-024-84608-5

This study aimed to elucidate the role of microRNA-92a-3p (miR-92a-3p) in the pathogenesis of adenomyosis. We examined how miR-92a-3p, found in exosomes derived from ectopic lesions, influences the behaviour of endometrial cells, dorsal roo…

other 2025
Journal of Obstetrics and Gynaecology Research ·doi:10.1111/jog.70111

AIM: This study aimed to compare clinical characteristics and evaluate diagnostic biomarkers in ovarian endometriosis, with a focus on thyroid autoimmunity associations. METHODS: A retrospective analysis of 885 patients (441 ovarian endome…

other 2024
Protein & cell ·doi:10.1093/procel/pwae012

Adenomyosis is a poorly understood gynecological disorder lacking effective treatments. Controversy persists regarding "invagination" and "metaplasia" theories. The endometrial-myometrial junction (EMJ) connects the endometrium and myometri…

preprint 2024
·doi:10.21203/rs.3.rs-3961335/v1
article 2024
International immunopharmacology ·doi:10.1016/j.intimp.2024.112366
article 2023
JAMA network open ·doi:10.1001/jamanetworkopen.2023.17860

Importance: Adenomyosis is a common chronic gynecological disorder, and its treatment is an unmet need. New therapies need to be developed. Mifepristone is being tested for adenomyosis treatment. Objective: To determine whether mifepristone…

article 2021
·doi:10.2139/ssrn.3897694
article 2021
Journal of cellular and molecular medicine ·doi:10.1111/jcmm.16261

Endometriosis is a benign, chronic inflammatory disease that commonly occurs in reproductive-aged women. Epithelial-mesenchymal transition (EMT) of endometrial epithelial cells plays an important role in the development of endometriosis. Re…

article 2020
International journal of medical sciences ·doi:10.7150/ijms.39252

Background: Adenomyosis is a quite common gynecological disorder and above 30% of patients have typical secondary and progressive dysmenorrhea. Current treatments still have many disadvantages and thereby the novel treatment aiming to relie…

article 2019
Journal of cellular and molecular medicine ·doi:10.1111/jcmm.14866

Adenomyosis is also called internal endometriosis and affects about 20% of reproductive-aged women. It seriously reduces life quality of patients because current drug therapies face with numerous challenges. Long-term clinical application o…

article 2019
Journal of pain research ·doi:10.2147/jpr.s205561

Purpose: Studies have shown that adenomyomectomy can effectively treat women with adenomyosis in a short period of time. However, the long-term efficacy of adenomyomectomy has rarely been reported. The objective of this study was to determi…

article 2014
European journal of obstetrics, gynecology, and reproductive biology ·doi:10.1016/j.ejogrb.2014.01.027
article 2012
Acta histochemica ·doi:10.1016/j.acthis.2012.08.006
article 2012

Angiogenesis is a prerequisite for the formation and development of endometriosis. Pigment epithelium derived factor (PEDF) is a natural inhibitor of angiogenesis. We previously demonstrated a reduction of PEDF in the peritoneal fluid, seru…

article 2012
PloS one ·doi:10.1371/journal.pone.0045223

Angiogenesis is a prerequisite for the formation and development of endometriosis. Pigment epithelium derived factor (PEDF) is a natural inhibitor of angiogenesis. We previously demonstrated a reduction of PEDF in the peritoneal fluid, seru…